Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination with Vincristine and Temozolomide in Adolescents and Young Adults with Relapsed or Refractory Sarcomas
- Conditions
- SarcomaSarcoma, EwingOsteosarcomaRhabdomyosarcomaDesmoplastic Small Round Cell TumorRefractory Sarcoma
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- David S Shulman, MD
- Target Recruit Count
- 63
- Registration Number
- NCT06709495
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
- Conditions
- Follicular Lymphoma
- Interventions
- Radiation: radiation therapyDrug: Tiselizumab
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Target Recruit Count
- 20
- Registration Number
- NCT06704555
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, Tianjin, China
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
- Conditions
- Marginal Zone Lymphoma(MZL)
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Fei Li
- Target Recruit Count
- 90
- Registration Number
- NCT06700798
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
- Conditions
- LymphomaPeripheral T Cell LymphomaAngioimmunoblastic T-cell LymphomaEnteropathy-Associated T-Cell LymphomaMonomorphic Epitheliotropic Intestinal T-Cell Lymphoma
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Eric Jacobsen, MD
- Target Recruit Count
- 24
- Registration Number
- NCT06692452
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
- Conditions
- Pleuropulmonary Blastoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Bone ScanOther: Patient ObservationProcedure: Ultrasound ImagingProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: Positron Emission Tomography
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 110
- Registration Number
- NCT06647953
- Locations
- 🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06630091
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-14
- Target Recruit Count
- 108
- Registration Number
- NCT06594640
- Locations
- 🇨🇳
Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin, China
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Conditions
- Large B-cell LymphomaB-cell Non-Hodgkin LymphomaMantle-cell LymphomaChronic Lymphocytic LeukaemiaSmall Lymphocytic Leukaemia
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 180
- Registration Number
- NCT06564038
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Conditions
- Neuroblastoma RecurrentLiposarcoma RecurrentEwing's Sarcoma RecurrentOsteosarcoma RecurrentRhabdomyosarcoma Recurrent
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 114
- Registration Number
- NCT06541262
- Locations
- 🇺🇸
Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania, United States
Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT06541665
- Locations
- 🇯🇵
Kindai University Hospital, Osakasayama-shi, Osaka, Japan
🇯🇵Institute of Science Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
🇯🇵National Hospital Organization Disaster Medical Center, Midori-cho, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.